Literature DB >> 265746

Prognotic significance of pretreatment proliferative activity in adult acute leukemia.

J S Hart, S L George, E Frei, G P Bodey, R C Nickerson, E J Freireich.   

Abstract

A statistical analysis of the prognostic significance of eight pretreatment variables was undertaken for 71 previously untreated adult patients with acute leukemia seen at M.D. Anderson Hospital over a 5 1/2-year period. None of the patients had received any prior therapy. Nearly all of the patients (68 of the 71) were treated with 4- or 5-day courses of arabinosyl-cytosine alone or in combination with cyclophosphamide, vincristine (oncovin) and prednisone (COAP). The pretreatment variables studied were age at diagnosis, the percent labeling index of the bone marrow leukemic cells, diagnosis, the highest temperature prior to start of treatment, the marrow clot section cellularity and smear differential percent of blasts, percent absolute marrow leukemic cell infiltrate and absolute number of blasts X 10(3)/mm3 in the peripheral blood. Fifty-one patients had acute myeloblastic leukemia (AML) and 20 patients had acute lymphoblastic leukemia (ALL). Using a statistical regression model approach, the only variables found to be of significant prognostic importance with respect to the probability of complete remission for AML patients were the pretreatment percent labeling index, the age of the patient and the highest temperature prior to start of treatment. Unlike AML, the initial percent labeling index did not appear to be of prognostic significance for ALL patients. AML patients with high labeling indices (larger than or equal to 9%) and young patients in general (especially those less than 40 years old) had the best remission rates. With respect to the length of complete remission and survival for all patients, the only important variables were the pretreatment percent labeling index and the age of the patient, respectively. Once in complete remission, an initially high labeling index was an unfavorable sign with respect to length of remission, regardless of the patient's diagnosis. The results of this study are supportive of studies in experimental systems demonstrating the importance of cytokinetic factors in the administration of chemotherapy and suggest that such factors may be of clinical importance in selecting approaches to therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 265746     DOI: 10.1002/1097-0142(197704)39:4<1603::aid-cncr2820390435>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Predicting chemosensitivity of tumors.

Authors:  J Mattern; K Wayss; M Volm
Journal:  Breast Cancer Res Treat       Date:  1986       Impact factor: 4.872

2.  Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.

Authors:  H M Kantarjian; B Barlogie; M J Keating; R R Hall; T L Smith; K B McCredie; E J Freireich
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

3.  Assessment of proliferative activity in leukaemic bone marrow using the monoclonal antibody Ki-67.

Authors:  D M White; A G Smith; J L Smith
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

4.  The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML).

Authors:  M Aglietta; P Sonneveld
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

5.  Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine.

Authors:  F Dolbeare; H Gratzner; M G Pallavicini; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

Review 6.  Prediction of response to cancer chemotherapy.

Authors:  M F Sarosdy; D D Von Hoff
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

7.  Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics.

Authors:  P P Brons; C Haanen; J B Boezeman; P Muus; R S Holdrinet; A H Pennings; H M Wessels; T de Witte
Journal:  Ann Hematol       Date:  1993-05       Impact factor: 3.673

8.  Serum thymidine kinase in acute leukaemia.

Authors:  H Hagberg; S Gronowitz; A Killander; C Källander; B Simonsson; C Sundström; G Oberg
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

9.  Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukaemia of childhood.

Authors:  J H Scarffe; I M Hann; D I Evans; P Morris Jones; M K Palmer; J S Lilleyman; D Crowther
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.